Evidence map›Paper›PMID 35296556›Full record

Trial reportJournal for immunotherapy of cancer2022

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.

Haiping Jiang, Xiongfei Yu, Ning Li, Mei Kong, Zhimin Ma, Donghui Zhou, Weibin Wang, Haohao Wang, Haiyong Wang, Kuifeng He and 11 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05648487 (A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy), which is not on this map. Cited by 77 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 7 pooled it
14.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05648487 phase2not yet recruitingnot on this mapstarted 2023, after this paper: background citation

A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Sintilimab in Gastric Cancer With Peritoneal Metastasis

TypeinterventionalSponsorAffiliated Cancer Hospital & Institute of Guangzhou Medical UniversityRan2023 to 2027Enrolled46ConditionsGastric CancerArmsHIPEC,anti-PD-1 antibody Sintilimab (Tyvyt®), Chemotherapy,Surgery
3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 7 syntheses or guidelines pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Haiping Jiang *Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiongfei Yu *Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Ning Li *Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Mei Kong *Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhimin MaDepartment of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Donghui ZhouDepartment of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Weibin WangDepartment of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Haohao WangDepartment of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Haiyong WangDepartment of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Kuifeng HeDepartment of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhongqi LiDepartment of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yimin LuDepartment of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jing ZhangDepartment of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Kui ZhaoDepartment of Nuclear Medicine, PET Centre, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yafei ZhangDepartment of Nuclear Medicine, PET Centre, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Nong XuDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Ziran LiDepartment of Medical Science and Strategy Oncology, Innovent Biologics, Inc, Suzhou, China.
Ying LiuDepartment of Medical Science and Strategy Oncology, Innovent Biologics, Inc, Suzhou, China.
Yan WangDepartment of Medical Science and Strategy Oncology, Innovent Biologics, Inc, Suzhou, China.
Yisen WangDepartment of Translational Medicine, Innovent Biologics, Inc, Suzhou, China.
Lisong TengDepartment of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China lsteng@zju.edu.cn.
First Affiliated Hospital Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors have greatly improved the prognoses of diverse advanced malignancies, including gastric and gastroesophageal junction (G/GEJ) cancer. However, the role of anti-programmed cell death protein-1 treatment in the neoadjuvant setting remains unclear. This phase 2 study aimed to evaluate sintilimab plus CapeOx as a neoadjuvant regimen in patients with advanced resectable G/GEJ adenocarcinoma. Eligible patients with resectable G/GEJ adenocarcinoma stage cT3-4NanyM0 were enrolled. Patients received neoadjuvant treatment with sintilimab (3 mg/kg for cases <60 kg or 200 mg for those ≥60 kg on day 1) plus CapeOx (oxaliplatin at 130 mg/m

Indexed as

AdenocarcinomaNeoadjuvant TherapyAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCapecitabineEsophagogastric JunctionHumansNeoplasm Recurrence, LocalOxaliplatinAntibodies, Monoclonal, HumanizedCapecitabineOxaliplatinsintilimabantibodies, neoplasmclinical trials as topicclinical trials, phase II as topicgastrointestinal neoplasmsimmunotherapy

Identifiers

PMID35296556
PMCPMC8928365
OpenAlexW4220843666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.